Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients — Piero Barbanti (2022) | RDL Network
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Article 2022 en
Authors
PB
Piero Barbanti
GE
Gabriella Egeo
CA
Cinzia Aurilia
Abstract
1 min read
A critical evaluation of headache characteristics indicating peripheral or central sensitization may help in predicting responsiveness to antiCGRP mAbs in HFEM and CM. A more precise pain profiling may represent a steppingstone for a mechanism-based approach and personalized treatment of migraine with compounds targeting specific molecular mechanisms.
Discussion(0)
No comments yet. Be the first to comment.